Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomized, Placebo- and Active-Comparator-Controlled, Single-Dose Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion in Subjects With Postherpetic Neuralgia.

Next Previous
Trial Profile

A Double-Blind, Randomized, Placebo- and Active-Comparator-Controlled, Single-Dose Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion in Subjects With Postherpetic Neuralgia.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jan 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KAI 1678 (Primary) ; Lidocaine
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors KAI Pharmaceuticals

Most Recent Events

  • 21 Apr 2010 New source identified and integrated ( ClinicalTrials.gov: US National Institutes of Health NCT01106716)
  • 21 Apr 2010 Planned patient number (24) added as reported by ClinicalTrials.gov.
  • 21 Apr 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top